Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy
| Autor: | Kristen A. Staggers, Carla M. Davis, Andrea C. Blackman, Aikaterini Anagnostou, Lauren Kronisch |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male medicine.medical_specialty Oral immunotherapy Adolescent Arachis medicine.medical_treatment Immunology Peanut allergy MEDLINE Administration Oral Quality of life Food allergy Internal medicine Surveys and Questionnaires medicine Immunology and Allergy Humans In patient Peanut Hypersensitivity Child Desensitization (medicine) business.industry United States Food and Drug Administration Allergens medicine.disease United States Desensitization Immunologic Child Preschool Research studies Quality of Life Female business |
| Zdroj: | Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 125(2) |
| ISSN: | 1534-4436 |
| Popis: | Background Peanut oral immunotherapy (POIT) is a novel and active form of treatment for patients with peanut allergy, with multiple research studies supporting its efficacy and safety. However, there are limited data available on changes in patients' quality of life (QoL) after successful desensitization. The Food and Drug Administration in the United States recently approved the first POIT drug for commercial use. Objective To evaluate the QoL of patients with peanut allergy receiving POIT in a real-world academic setting. Methods Twenty-one patients aged 4 to 17 years with a physician-established diagnosis of peanut allergy were offered POIT. Quality-of-life scores were assessed with the use of a validated Food Allergy Quality of Life questionnaire. Changes in quality-of-life scores were measured for each patient before and after POIT. The Wilcoxon signed-rank test was used to compare the distributions of scores before and after therapy. Results We noted a statistically significant drop (reflecting improvement in the QoL) in the overall Food Allergy Quality of Life score (median 3.70 vs 2.97, P = .049) between baseline and successful desensitization to 300-mg peanut protein. In addition, the Social and Dietary Limitations subscale score (median 4.33 vs 2.89, P = .02) and the Food Allergy Independent Measure score (median 3.17 vs 2.22, P = .001) also improved significantly after therapy. Conclusion We report a significant improvement in the overall QoL before and after POIT treatment, with fewer concerns about accidental exposures and severity of allergic reactions as well as fewer limitations in dietary choices and social interactions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|